FDA grants accelerated approval for dostarlimab in locally advanced rectal cancer with dMMR tumors

● REGULATORY

The immunotherapy Jemperli (dostarlimab-gxly) received accelerated approval for previously untreated stage II or III locally advanced rectal cancer with mismatch repair deficient tumors, potentially allowing some patients to avoid chemotherapy, radiation, and surgery. (FDA Press Releases)